Bank Julius Baer & Co
IBRX icon

Bank Julius Baer & Co’s ImmunityBio IBRX Stock Holding History

Bank Julius Baer & Co’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,500
Closed -$15K – 856
2021
Q3 		$15K Buy
1,500
+29
+2% +$319 ﹤0.01% 762
2021
Q2 		$21K Sell
1,471
-29
-2% -$479 ﹤0.01% 754
2021
Q1 		$36K Sell
1,500
-526
-26% -$13.6K ﹤0.01% 699
2020
Q4 		$27K Buy
+2,026
New +$19.5K ﹤0.01% 733

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank Julius Baer & Co's IBRX Position: Q4 2021 in Review

Bank Julius Baer & Co sold out of ImmunityBio (IBRX) in Q4 2021, closing a stake of 1,500 shares — an estimated $15K sold.

Bank Julius Baer & Co first reported a position in IBRX in Q4 2020 and held it in 4 quarters. The position peaked at $36K in Q1 2021. 141 funds tracked by Wall St. Rank hold IBRX as of Q4 2021.

  • Bank Julius Baer & Co reported no remaining ImmunityBio position as of Q4 2021 after selling out during the quarter.
  • Bank Julius Baer & Co sold 1,500 ImmunityBio shares in Q4 2021, an estimated $15K.
  • Bank Julius Baer & Co first reported a position in ImmunityBio in Q4 2020 and held it in 4 quarters.
  • Bank Julius Baer & Co's ImmunityBio position peaked at $36K in Q1 2021.
  • 141 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2021.

Based on Bank Julius Baer & Co's 13F filing for Q4 2021, filed 15 Feb 2022.